{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T17:02:32Z","timestamp":1782493352053,"version":"3.54.5"},"reference-count":23,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T00:00:00Z","timestamp":1738713600000},"content-version":"vor","delay-in-days":4,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009601","name":"Beijing Municipal Administration of Hospitals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["7232051"],"award-info":[{"award-number":["7232051"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81970111"],"award-info":[{"award-number":["81970111"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.rpth.2025.102702","type":"journal-article","created":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T17:56:05Z","timestamp":1739296565000},"page":"102702","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Stepwise response-guided treatment protocol superior to thrombopoietin receptor agonist-based second-line therapy for severe persistent\/chronic immune thrombocytopenia: a\u00a0multicenter prospective study from China"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5611-9188","authenticated-orcid":false,"given":"Lingling","family":"Fu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1299-9008","authenticated-orcid":false,"given":"Xi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhifa","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyao","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoling","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6759-075X","authenticated-orcid":false,"given":"Jie","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4030-209X","authenticated-orcid":false,"given":"Runhui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpth.2025.102702_bib1","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1182\/blood.2020006480","article-title":"An update on pediatric ITP: differentiating primary ITP, IPD, and PID","volume":"140","author":"Grace","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2025.102702_bib2","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1182\/bloodadvances.2019000812","article-title":"Updated international consensus report on the investigation and management of primary immune thrombocytopenia","volume":"3","author":"Provan","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2025.102702_bib3","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1016\/S0140-6736(15)61107-2","article-title":"Eltrombopag for children with\u00a0chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial","volume":"386","author":"Grainger","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.rpth.2025.102702_bib4","first-page":"2867","article-title":"Prolonged response after TPO-RA discontinuation in primary ITP: results of a prospective multicenter study","volume":"141","author":"Guillet","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2025.102702_bib5","doi-asserted-by":"crossref","first-page":"e315","DOI":"10.1016\/S2352-3026(15)00114-3","article-title":"Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study","volume":"2","author":"Bussel","year":"2015","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.rpth.2025.102702_bib6","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1007\/s00277-022-04804-z","article-title":"Eltrombopag in pediatric chronic and refractory ITP: data from a retrospective multicenter study from Lebanon","volume":"101","author":"Noun","year":"2022","journal-title":"Ann Hematol"},{"key":"10.1016\/j.rpth.2025.102702_bib7","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.29006","article-title":"An escalating treatment strategy for children with severe chronic immune thrombocytopenia: preliminary report from a single center","volume":"68","author":"Fu","year":"2021","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.rpth.2025.102702_bib8","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/ped4.12305","article-title":"Editorial Board, Chinese Journal of Pediatrics. Adapted guideline for the diagnosis and treatment of primary immune thrombocytopenia for Chinese children (2021)","volume":"6","year":"2022","journal-title":"Pediatr Investig"},{"key":"10.1016\/j.rpth.2025.102702_bib9","doi-asserted-by":"crossref","first-page":"4190","DOI":"10.1182\/blood-2010-08-302984","article-title":"The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia","volume":"117","author":"Neunert","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2025.102702_bib10","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/ajh.27080","article-title":"Avatrombopag for adults with early versus chronic immune thrombocytopenia","volume":"99","author":"Virk","year":"2024","journal-title":"Am J Hematol"},{"key":"10.1016\/j.rpth.2025.102702_bib11","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/bjh.18545","article-title":"Evaluating the impact of thrombopoietin receptor agonist medications on patient outcomes and quality of life in paediatric immune thrombocytopenia through semi-structured interviews","volume":"200","author":"Livingston","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.rpth.2025.102702_bib12","first-page":"6422","article-title":"Recommendations for the clinical approach to immune thrombocytopenia: Spanish ITP Working Group (GEPTI)","volume":"12","author":"Mingot-Castellano","year":"2023","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.rpth.2025.102702_bib13","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.29447","article-title":"Thrombopoietin receptor agonists and rituximab for treatment of pediatric immune thrombocytopenia: a systematic review and meta-analysis of prospective clinical trials","volume":"69","author":"Ayad","year":"2022","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.rpth.2025.102702_bib14","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/ajh.27131","article-title":"Sustained response off-treatment in eltrombopag-treated adult patients with ITP who are refractory or relapsed after first-line steroids: primary, final, and ad-hoc analyses of the phase II TAPER trial","volume":"99","author":"Cooper","year":"2024","journal-title":"Am J Hematol"},{"key":"10.1016\/j.rpth.2025.102702_bib15","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/bjh.18842","article-title":"Sustained response off treatment in eltrombopag for children with persistent\/chronic primary immune thrombocytopenia: a multicentre observational retrospective study in China","volume":"202","author":"Wang","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.rpth.2025.102702_bib16","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1111\/bjh.18893","article-title":"Combining thrombopoietin receptor agonists with immunosuppressive drugs in adult patients with multirefractory immune thrombocytopenia, an update on the French experience","volume":"202","author":"ECrickx","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.rpth.2025.102702_bib17","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1111\/bjh.16426","article-title":"Combination of thrombopoietin receptor agonists, immunosuppressants and intravenous immunoglobulin as treatment of severe refractory immune thrombocytopenia in adults and children","volume":"189","author":"Gudbrandsdottir","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.rpth.2025.102702_bib18","first-page":"26","article-title":"The escalating treatment strategy improve the efficacy of chronic immune thrombocytopenia in children from a single-center","volume":"28","author":"Hu","year":"2023","journal-title":"J China Pediatr Blood Cancer"},{"key":"10.1016\/j.rpth.2025.102702_bib19","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/ajh.26497","article-title":"Cost-effectiveness of second-line therapies in adults with chronic immune thrombocytopenia","volume":"98","author":"Goshua","year":"2023","journal-title":"Am J Hematol"},{"key":"10.1016\/j.rpth.2025.102702_bib20","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1159\/000510676","article-title":"Tapering and discontinuation of thrombopoietin receptor agonist therapy in patients with immune thrombocytopenia: results from a modified Delphi panel","volume":"144","author":"Cooper","year":"2021","journal-title":"Acta Haematol"},{"key":"10.1016\/j.rpth.2025.102702_bib21","doi-asserted-by":"crossref","DOI":"10.1080\/16078454.2023.2210906","article-title":"Pediatric immune thrombocytopenia: a focus on eltrombopag as second-line therapy","volume":"28","author":"Palumbo","year":"2023","journal-title":"Hematology"},{"key":"10.1016\/j.rpth.2025.102702_bib22","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/ajh.25125","article-title":"Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: results of two phase 3, randomized, placebo-controlled trials","volume":"93","author":"Bussel","year":"2018","journal-title":"Am J Hematol"},{"issue":"Suppl","key":"10.1016\/j.rpth.2025.102702_bib23","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1097\/01.HS9.0000852076.33574.89","article-title":"PB2313: daratumumab as a treatment for adult immune thrombocytopenia: a phase II study with safety run-in (the DART study) [abstract]","volume":"6","author":"Tsykunova","year":"2022","journal-title":"HemaSphere"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037925000263?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037925000263?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T19:14:51Z","timestamp":1762629291000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037925000263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S2475037925000263"],"URL":"https:\/\/doi.org\/10.1016\/j.rpth.2025.102702","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stepwise response-guided treatment protocol superior to thrombopoietin receptor agonist-based second-line therapy for severe persistent\/chronic immune thrombocytopenia: a\u00a0multicenter prospective study from China","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpth.2025.102702","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}],"article-number":"102702"}}